Progestins in hormonal replecement therapy - new perspectives

Jacek Tomaszewski; Włodzimierz Baranowski

eISSN: 2299-0038
ISSN: 1643-8876

Menopause Review/Przegląd Menopauzalny

Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

2/2003
vol. 2

Send email

Copy url:

abstract:

Progestins in hormonal replecement therapy - new perspectives

Jacek Tomaszewski

,

Włodzimierz Baranowski

(Prz Menopauz 2003, 2: 12–17)

Online publish date: 2003/04/11

View full text Get citation

In the last years there has been an extraordinary development in the synthesis of new progestins. The action of progestins is a function of many factors: its structure, activity, affinity to the progesterone or to the other steroids receptors, the target tissue considered, dose, and metabolic transformation. Several risks are attributed to progestins as a class-effect; however, progestogens used in hormonal replacement therapy have varying pharmacological properties and do not induce the same side effects. Newly synthesized progestins (19-norprogesterone and 18α-spironolactone derivatives) do not bind to the androgen receptor and do not exert an androgenic side effect. Selection molecules having no estrogenic, androgenic or glucocorticoid effects should allow a larger use of the progestins in HRT without any major drawback.

keywords:

Progestins in hormonal replecement therapy - new perspectives

Jacek Tomaszewski , Włodzimierz Baranowski

menopause, hormonal replacement therapy, progestins

Jacek Tomaszewski

,

Włodzimierz Baranowski